Sustained response to mepolizumab in refractory Churg-Strauss syndrome
- 1 January 2010
- journal article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 125 (1), 267-270
- https://doi.org/10.1016/j.jaci.2009.10.014
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Mepolizumab and Exacerbations of Refractory Eosinophilic AsthmaThe New England Journal of Medicine, 2009
- Mepolizumab for Prednisone-Dependent Asthma with Sputum EosinophiliaThe New England Journal of Medicine, 2009
- Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levelsJournal of Allergy and Clinical Immunology, 2008
- Treatment of Patients with the Hypereosinophilic Syndrome with MepolizumabThe New England Journal of Medicine, 2008
- Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg‐Strauss syndromeArthritis & Rheumatism, 2005
- Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic responseThe Lancet, 2000
- Serum Interleukin-5 Levels in a Case with Allergic Granulomatous Angiitis.Internal Medicine, 1997